The Science of MS Management: Use of Imaging Technologies in MS
The Science of MS Management: Use of Imaging Technologies in MS – Predicting Disease Progression and Response to Therapy
Corey C. Ford, MD, PhD; Matilde Inglese, MD, PhD; G.R. Wayne Moore, MD, CM
|CME/CE Released: 08/31/2013; Valid for credit through 08/31/2014|
|Faculty and Disclosures|
|Corey C. Ford, MD, PhD|
Dr. Ford has disclosed the following financial relationships:
Sources of Funding for Research: Biogen Idec, Elan, Genentech, Genzyme, Janssen, Novartis, Ono Pharmaceutical, Sanofi Aventis, Serono, and Teva CNS.
Consulting Agreements: Biogen Idec, Novartis, and Teva CNS.
Matilde Inglese, MD, PhD
Dr. Inglese has disclosed the following financial relationships:
Sources of Funding for Research: Novartis.
G.R. Wayne Moore, MD, CM
Dr. Moore has disclosed no relevant financial relationships.
ReviewerLaurie Scudder, DNP, NP
Laurie Scudder has disclosed no relevant financial relationships.
Planners and Managers
The following planners and managers have no conflicts of interest to disclose: Joseph J. D'Onofrio, Frank Marino, Nancy Monson, Katherine Wandersee.
|This publication is targeted to neurologists who have an interest in treating multiple sclerosis (MS).|
|Upon completion of this educational activity, the participant should be able to: |
- Assess current outcomes data for the latest MRI techniques and newer imaging technologies in MS
- Describe applicability of newer imaging technologies to clinical practice in MS
- Describe results of MRI and other imaging outcomes from research involving new and emerging MS disease-modifying agents
- Discuss research about the clinical correlations of brain atrophy with MS symptoms and disease progression
|Disclosure of Non-endorsement of Products|
Approval does not imply endorsement by the CMSC or ACCME of any commercial products discussed in conjunction with an educational activity.
Disclosure of Unlabeled Use
This CME activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC, Teva CNS, and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC, Teva CNS, or Delaware Media Group.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.
|Accreditation and Designation|
|This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Consortium of Multiple Sclerosis Centers (CMSC) and the Delaware Media Group. The CMSC is accredited by the ACCME to provide continuing medical education for physicians.|
The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: August 31, 2013
Credit for this program expires on August 31, 2014.
|Method of Participation|
|Follow these steps to earn CME credit: |
Code: CMSC-DELMED 2013/2
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online or printed out.
- Choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. The CMSC encourages you to complete the Activity Evaluation to provide feedback for future programming.
|Jointly sponsored by the Consortium of Multiple Sclerosis Centers and Delaware Media Group.|
This continuing education publication is supported by an educational grant from Teva CNS.
For questions relating to CME, please contact the CMSC at (201) 487-1050 or email email@example.com.
|The minimum requirements for viewing an on-line book is an active internet connection and Flash (free software from Adobe) version 10 or higher.|
|Link to the Program|